Clinical Trial Update: A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of OBI-3424 in advanced solid tumors, including pancreatic adenocarcinoma, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• OBI-3424

Snippet

Sponsor: OBI Pharma, Inc | Conditions: Solid Tumor, Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: TERMINATED